Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -3.1% | 5.8% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | 195.3 |
PEG | n/a | n/a |
Pr/Revenue | 1.9 | 1.8 |
Pr/Book | 1.2 |
Latest | F'cast | |
---|---|---|
Revenue | 7.5% | 7.2% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 181.72 | 10.52 | 0.22p | 197.6 | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 201.96 | 20.00 | 1.06p | 42.1 | 0.1 | +370% | n/a | 0.0% |
30-Sep-26 | 225.13 | 31.33 | 2.89p | 15.4 | 0.1 | +174% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Total Voting Rights | 28-Mar-2024 | 12:00 | RNS |
Form 8.3 - Benchmark Holdings plc | 22-Mar-2024 | 11:51 | RNS |
Form 8.5 (EPT/RI) - Benchmark Holdings Plc | 22-Mar-2024 | 10:52 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 44.45p |
Change Today | -0.050p |
% Change | -0.11 % |
52 Week High | 47.30 |
52 Week Low | 34.00 |
Volume | 16,376 |
Shares Issued | 739.55m |
Market Cap | £328.73m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
No dividends found |
Time | Volume / Share Price |
16:14 | 3 @ 43.03p |
15:43 | 7,236 @ 43.03p |
13:48 | 57 @ 43.03p |
13:39 | 50 @ 43.00p |
12:17 | 8,000 @ 44.24p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research